Hong Luo

发表

Circulating tumor DNA genomic profiling reveals the complicated olaparib-resistance mechanism in prostate cancer salvage therapy: A case report

Xiao-Tian Zhang, F. Yuan, Hong Zhou, 2022, World journal of clinical cases.

Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial

T. Chong, X. Qin, D. Ji, 2022, BMC Medicine.

Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.

Ying Cheng, Jiyan Liu, D. Ye, 2019, The oncologist.

Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study

D. Ye, N. Xing, Quanren Wang, 2022, Journal for ImmunoTherapy of Cancer.

Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study

D. Ye, N. Xing, Hai-Liang Zhang, 2021, Clinical Cancer Research.

Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial

Jiyan Liu, D. Ye, S. Qin, 2020, Frontiers in Oncology.

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Jiyan Liu, J. Ying, X. Yao, 2020, Clinical Cancer Research.

Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT).

Zhiquan Hu, F. Zhou, Peng-Yu Chen, 2022, European journal of cancer.